β-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction
- 1 November 2014
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 7 (6) , 872-881
Abstract
Background—: The long-term efficacy of β-blockers in patients with and without myocardial infarction (MI) is controversial. Methods and Results—: This is post hoc analysis from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial of 4772 patients with prior MI, 7804 patients with known atherothrombosis, and 2101 patients with risk factors alone but without heart failure. Primary outcome was a composite of nonfatal MI, stroke, or cardiovascular mortality. The cohorts were divided into 2 groups based on baseline β-blocker use. In the propensity score–matched prior MI cohort, after 28 months of follow-up, β-blocker use was associated with a 31% lower risk of the primary outcome (70 [7.1%] versus 100 [10.2%]; hazards ratio, 0.69; 95% confidence interval, 0.50–0.94; P =0.021), driven by a lower risk of recurrent MI (33 [3.4%] versus 48 [4.9%]; hazards ratio, 0.62; 95% confidence interval, 0.39–1.00; P =0.049) with no difference in mortality (52 [5.3%] versus 66 [6.7%]; P =0.20). In the known atherothrombotic disease and the risk factors alone cohorts, β-blocker use was not associated with lower ischemic outcomes, whereas a trend toward a higher risk of stroke (3.5% versus 1.5%; hazards ratio, 2.13; 95% confidence interval, 0.92–4.92; P =0.079) was observed in the risk factors alone cohort. This higher stroke risk was significant in the regression model adjusted to the propensity score (hazards ratio, 2.69; 95% confidence interval, 1.33–5.44; P =0.006) and in the multivariable models. Conclusions—: β-blocker use in patients with prior MI but no heart failure was associated with a lower composite cardiovascular outcome driven by lower risk of recurrent MI with no difference in mortality. However, β-blocker use was not associated with lower cardiovascular events in those without MI, with a suggestion of inferior outcome with regard to stroke risk. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT00050817.Keywords
This publication has 30 references indexed in Scilit:
- Are β-blockers truly helpful in patients with CAD?Nature Reviews Cardiology, 2012
- Impact of Heart Rate on Central Aortic Pressures and HemodynamicsJACC, 2009
- Beta-Blockers for Primary Prevention of Heart Failure in Patients With HypertensionJACC, 2008
- Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudyAmerican Heart Journal, 2008
- Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA TrialJACC, 2007
- Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methodsEuropean Heart Journal, 2006
- Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform EffectAmerican Journal of Epidemiology, 2005
- A Comparison of the Two β-Blockers Carvedilol and Atenolol on Left Ventricular Ejection Fraction and Clinical Endpoints after Myocardial InfarctionCardiology, 2005
- Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trialAmerican Heart Journal, 2004
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983